**bsm-41470M** **[ Primary Antibody ]**

# beta-Amyloid(1-42) Mouse mAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

## DATASHEET

**Host:** Mouse
**Isotype:** IgG2b
**Clonality:** Monoclonal
**CloneNo.:** 6C8
**GeneID:** 351
**SWISS:** P05067
**Target:** beta-Amyloid(1-42)
**Immunogen:** KLH conjugated synthetic peptide derived from human beta-Amyloid(1-42): 672-713/770 or 1-42/42.
**Purification:** affinity purified by Protein A
**Concentration:** 1mg/ml
**Storage:** Size : 50ul/100ul/200ul
0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Size : 200ug (PBS only)
0.01M PBS
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
**Background:** The cerebral and vascular plaques associated with Alzheimer's disease are mainly composed of Amyloid beta peptides. beta Amyloid is derived from cleavage of the Amyloid precursor protein and varies in length from 39 to 43 amino acids. beta Amyloid [1-40], beta Amyloid [1-42], and beta Amyloid [1-43] peptides result from cleavage of Amyloid precursor protein after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last Amyloid precursor protein processing step. beta Amyloid [1-40], beta Amyloid [1-42], and beta Amyloid [1-43] peptides are major constituents of the plaques and tangles that occur in Alzheimer's disease. beta Amyloid antibodies and peptides have been developed as tools for elucidating the biology of Alzheimer's disease.

**Applications:** **WB** (1:500-2000)
**IHC-P** (1:500-5000)
**IHC-F** (1:500-5000)
**IF** (1:200-5000)
**Reactivity:** Human (predicted: Mouse, Rat)
**Predicted MW.:** 4.4 kDa
**Subcellular Location:** Cell membrane

## VALIDATION IMAGES




100 ng Aβ1-42 Peptide (bs-0107P) per lane probed with beta-Amyloid(1-42) polyclonal antibody respectively, unconjugated (bsm-41470M) at 1:1000 dilution and 4°C overnight incubation. Followed by corresponding conjugated secondary antibody incubation at r.t. for 60 min.




Positive sample（left）：Alzheimer's Disease Brain Negative sample（right）：Normal Human Brain Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Incubation with (beta-Amyloid(1-42)) Monoclona Antibody, Unconjugated (bsm-41470M) at 1:1000 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0024) instructionsand DAB staining.

## SELECTED CITATIONS

- **[IF=0]** Nalla Swathi. et al. Defensive Impact of Kaempferide Against Neurodegenerative Studies: In Vitro and In Vivo Investigations. Chemistry Africa-A Journal of the Tunisian Chemical Society. 2023 Apr;:1-11 WB ;Rat. 10.1007/s42250-023-00673-9